Mechanism
How semaglutide works: GLP-1 receptor agonism
Semaglutide mimics a natural gut hormone to lower blood sugar and reduce appetite. Here is what that means in the body.
Quick Answer
Semaglutide is a GLP-1 receptor agonist: it activates the receptor for glucagon-like peptide-1, a hormone the gut releases after eating. This boosts glucose-dependent insulin release, suppresses glucagon, slows gastric emptying and increases satiety — lowering blood sugar and reducing food intake. It is FDA-approved as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (obesity); compounded semaglutide is not FDA-approved.
Key Facts
- Drug class: GLP-1 receptor agonist (incretin mimetic)
- Brands: Ozempic & Rybelsus (diabetes), Wegovy (obesity), by Novo Nordisk
- Effects: glucose-dependent insulin, glucagon suppression, slowed gastric emptying, appetite reduction
- Hypoglycemia risk is low alone because insulin release is glucose-dependent
- Compounded semaglutide is not FDA-approved
The incretin system semaglutide imitates
After a meal, the gut releases glucagon-like peptide-1 (GLP-1), an incretin hormone that signals the pancreas to release insulin in proportion to the meal. Natural GLP-1 is broken down within minutes by the enzyme DPP-4. Semaglutide is engineered to resist that breakdown and to bind albumin, so it stays active far longer and can be dosed weekly (injection) or daily (oral).
What activating the GLP-1 receptor does
GLP-1 receptor activation has several coordinated effects: it stimulates glucose-dependent insulin secretion (insulin rises mainly when blood glucose is high), suppresses glucagon (which would otherwise raise blood sugar), slows the rate at which the stomach empties, and acts on appetite centres in the hypothalamus and brainstem to increase fullness. Because the insulin effect is glucose-dependent, semaglutide alone carries a low risk of hypoglycemia.
From blood sugar to weight loss
In type 2 diabetes these actions lower A1c; in obesity, the appetite and satiety effects reduce spontaneous calorie intake, which — sustained over months — produces weight loss. In the STEP obesity trials, weekly semaglutide 2.4 mg produced mean weight reductions far larger than placebo (see STEP 1). The same mechanism explains the most common side effects, which are gastrointestinal.
What mechanism does and doesn't tell you
Understanding how a drug can work is not the same as knowing it is right for any individual. Semaglutide has contraindications and risks (see our thyroid warning and GI side-effect explainers), and only a licensed clinician can judge suitability. Compounded semaglutide is not FDA-approved and is not the same product as Wegovy, Ozempic or Rybelsus.
Frequently asked questions
Is semaglutide the same as Ozempic and Wegovy?
Semaglutide is the active ingredient in Ozempic and Rybelsus (for type 2 diabetes) and Wegovy (for obesity), all made by Novo Nordisk. Compounded semaglutide is a different, non-FDA-approved preparation.
Does semaglutide cause low blood sugar?
On its own the risk is low because its insulin effect is glucose-dependent. The risk rises when it is combined with insulin or sulfonylureas.
References
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- U.S. Food and Drug Administration. Wegovy, Ozempic and Rybelsus (semaglutide) prescribing information. Novo Nordisk.
Citations are for educational reference; this article summarizes published research in plain language and is not medical advice.
Bottom Line
Semaglutide works by activating the GLP-1 receptor — boosting glucose-dependent insulin, slowing the gut and reducing appetite. It is effective in trials, but suitability is an individual clinical decision, and compounded versions are not FDA-approved.
Related from the Journal
Appetite & gastric emptying
How semaglutide reduces hunger.
STEP 1 results
Weight loss in the landmark obesity trial.
Semaglutide vs semaglutide
Two leading GLP-1 medicines compared.